BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells

Imatinib (IMT), a specific tyrosine kinase inhibitor (TKI), has drastically changed the treatment strategy for Ph+ ALL (Philadelphia chromosome-positive acute lymphoblastic leukemia). However, TKI resistance remains a serious problem for patient prognosis. Here, a Ph+ ALL cell line NphA2 and the IMT...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Chisato, Sobue, Sayaka, Aoyama, Yuka, Mizutani, Naoki, Kawamoto, Yoshiyuki, Nishizawa, Yuji, Ichihara, Masatoshi, Abe, Akihiro, Hayakawa, Fumihiko, Suzuki, Motoshi, Nozawa, Yoshinori, Murate, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068087/
https://www.ncbi.nlm.nih.gov/pubmed/30073206
http://dx.doi.org/10.1016/j.bbrep.2018.07.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068087/
https://www.ncbi.nlm.nih.gov/pubmed/30073206
http://dx.doi.org/10.1016/j.bbrep.2018.07.001

Ejemplares similares